Form 10-Q Corbus Pharmaceuticals For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Corbus Pharma (CRBP) Tops Q3 EPS by 2c
November 11, 2015 7:33 AM ESTCorbus Pharma (NASDAQ: CRBP) reported Q3 EPS of ($0.06), $0.02 better than the analyst estimate of ($0.08).
Expected Near-Term Milestones
Continue to screen and enroll patients in both the Phase 2 studies in CF and in systemic sclerosis to remain on track... MoreCorbus Pharma (CRBP) Files $100M Mixed Shelf
November 11, 2015 6:51 AM ESTCorbus Pharma (NASDAQ: CRBP) filed a registration with the U.S. SEC to sell up to $100 million of mixed securities.
... More